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Editorial on the Research Topic
Advances in Head and Neck Cancer Immunology and Immunotherapy
Head and neck cancers are a group of malignancies that affect the head and neck region. These
include cancers of the oral cavity, oropharynx, larynx, lips, sinuses, and nasal cavity. The incidence
of head and neck cancer is on the rise which is mainly attributed to changes in risk factors including
increased alcohol and tobacco consumption and betel chewing habits in certain parts of the world.
Additionally, human papilloma virus (HPV) infections have contributed to the rise of head and
neck cancers, in particular oropharyngeal cancers, especially in younger patients.
Despite advances in cancer diagnosis and treatment, the mortality rate of head and neck cancer
remains unchanged. The high mortality rate is mainly attributed to late diagnosis, and the lack of
effective treatments for late stage cancers.
Cancer immunotherapy is among the greatest advances in cancer therapy. Various treatment
modalities that target different components of the immune system have proven successful in
controlling disease progression and even producing long lasting cures in some types of cancer.
Cancer immunotherapy’s biggest successes were reported in melanoma and lung cancer. However,
many other cancer types are benefiting from the advances in cancer immunotherapy including
head and neck cancer. In fact, several immunotherapies have been approved for the treatment of
head and neck cancer, including immune checkpoint inhibitors for the management of recurrent
or metastatic cancers.
Although the success of cancer immunotherapy cannot be disputed, many patient responses
are transient and short lived. This can be explained by different immune escape mechanisms
deployed by cancer cells including dampening the immune response through modulating immune
checkpoints, in addition to the recruitment and de novo differentiation of suppressive immune cells
such as regulatory CD4 T cells.
In this research topic, two review articles (Forster and Devlin; Ward et al.) discussed the use of
immune checkpoint inhibitors in the treatment of head and neck cancer.
Forster and Devlin provided a review of different co-inhibitory and co-stimulatory checkpoints
that could be targeted by immune checkpoint inhibitors in the context of immunotherapy. Their
article included a review of the role of the PD-1/PDL-1 axis and GITR in cancer immunology and
immunotherapy. The review article by Forster and Devlin presented a comprehensive and exciting
review of different therapeutic combinations with checkpoint inhibitors, including different
immune modulators, viral therapies, and chemoradiotherapy. The review then summarized
the adverse effects associated with immune checkpoint inhibitor therapy and highlighted the
importance of biomarkers for the prediction of disease progression and response to therapy.
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In their manuscript, Ward et al. provided an overview
of the timeline for FDA approvals of different immune
checkpoint inhibitors in the treatment of different cancers. The
manuscript detailed the history, function, and application of
anti-CTLA-4, anti-PD-1, and anti-PDL-1 antibodies in cancer
immunotherapy before providing an in depth review of the
use of immune checkpoint inhibitors in head and neck cancer.
The manuscript by Ward et al. provided an interesting
review of possible modifications of existing checkpoint
inhibitors including antibodies that target a soluble isoform
of CTLA-4 (sCTLA-4).
The presence of suppressive immune cells in the tumor
microenvironment, and in particular regulatory CD4T cells, has
been shown to adversely affect the patient prognosis and the
anti-tumor immune response. Several strategies are under study
to selectively target these suppressive cells as part of cancer
immunotherapy. However, there is some conflicting evidence
in the literature regarding the role of regulatory CD4T cells
in head and neck cancer. The systematic review by O’Higgins
et al. investigated this controversy and systematically analyzed
the available evidence. Their findings revealed a deficiency in
fully characterizing regulatory T cell phenotypes in the studied
head and neck tumors, especially with regard to HPV status,
which could contribute to the discrepancy in describing the role
of regulatory CD4T cells in tumor progression. Furthermore, the
findings of the systematic review by O’Higgins et al. uncovered a
real need for developing robust markers for phenotyping T cells
and for detecting regulatory CD4T cells systemically and within
the tumor microenvironment.
HPV positive head and neck cancers represent a particularly
appealing target for cancer immunotherapy because of their
intrinsic immunogenicity. In addition to the immune response
mounted in response to the virus itself, tumors positive for HPV
over-express E6 and E7 which can be recognized by the immune
system as non-self antigens and can therefore be ideal targets for
vaccine based immunotherapies. In their review article, Wang
et al. discussed the use of cancer vaccines in the prevention
and the treatment of head and neck cancer. They discussed the
differences between HPV positive and HPV negative tumors and
provided a comprehensive review into various target antigens
(viral antigens, neoepitopes, and tumor associated antigens)
and different vaccine platforms (DNA, mRNA, peptide, viral,
bacterial vector, and cellular vaccines).
Measures for predicting patient survival in head and neck
cancer are still lacking. Wichmann et al.’s original research article
reported the potential use of a Human Leucocyte Antigen (HLA)
score to predict progression free survival in head and neck
cancer patients. In their study, Wichmann et al. used HLA
traits known to be predictors of progression free survival to
build a scoring system using genetic information from HLA
typing for predicting prognosis. The findings of their study
have significant clinical potential for predicting relapse and for
the stratification of patients for clinical trials and informing
personalized treatment.
Given the complexity of the immune response to cancer, no
single therapeutic agent is capable of enhancing the effector
arms of the immune response while simultaneously targeting
the suppressive arm. The collection of articles in this research
topic suggests a role for combination therapies in the treatment
and management of head and neck cancer. Many clinical trials
are ongoing that are testing various combinations of modulators
of the immune system for the management of head and
neck cancer.
The combination of diverse immunotherapies that target
different arms of the immune response is gaining acceptance in
the clinical setting and could potentially provide a solution for
sustaining short lived anti-tumor immune responses.
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